How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pixantrone-cyclophosphamide-vincristine-rituximab-prednisone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

pixantrone, cyclophosphamide, vincristine, rituximab, prednisone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pixantrone, cyclophosphamide, vincristine, rituximab, prednisone (pixantrone, cyclophosphamide, vincristine, rituximab, prednisone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anthracycline. Area: Oncology.

phase 3 anthracycline DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

pixantrone, cyclophosphamide, vincristine, rituximab, prednisone (pixantrone, cyclophosphamide, vincristine, rituximab, prednisone) — CTI BioPharma. Pixantrone is a synthetic anthracenedione that intercalates DNA, thereby inhibiting DNA replication and transcription.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
pixantrone, cyclophosphamide, vincristine, rituximab, prednisone TARGET	pixantrone, cyclophosphamide, vincristine, rituximab, prednisone	CTI BioPharma	phase 3	anthracycline	DNA
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01
Vidaza	azacitidine	Bristol-Myers Squibb	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2004-01-01
Zymar	GATIFLOXACIN	Allergan	marketed		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-05-14 — Vidaza · 12053482 · Method of Use · US
2029-05-14 — Vidaza · 11571436 · Formulation · US
2030-06-03 — Vidaza · 8846628 · Formulation · US

Sponsor landscape (anthracycline class)

CTI BioPharma · 1 drug in this class
GBG Forschungs GmbH · 1 drug in this class
National Cancer Institute, Naples · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pixantrone, cyclophosphamide, vincristine, rituximab, prednisone — Competitive Intelligence Brief. https://druglandscape.com/ci/pixantrone-cyclophosphamide-vincristine-rituximab-prednisone. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab